Titre :Public health and genetic Résumé : About the question of the necessity of a genetic governance in public health. Intervenant : Emmanuelle RIAL-SEBBAG SCD Médecine.

Professor Richard Rodger has written extensively about the social and economic history of British cities in the nineteenth and twentieth centuries. At the heart of this research is an interest in the

Bernard Swynghedauw defines the biodiversity, the health, and the disease. He evidences the importance of the environmental and / or genetic factors in the appearance of diseases. He also links the

The public health and the patient education in France presented by GIRER Marion. SCD Médecine.

Ecole Européenne d'été 2009 VA - 2035, a public health issue : duties to procreate by Marieen Eijkholt. Website of the European Cour of Human Rights : http://www.echr.coe.int SCD Médecine.

Bernard Swynghedauw explores with us a still quite unknown biodiversity, which plays an essential role for our development: the microbiota. It consists of all the microorganisms living in our organism

What are international legal instruments to fight against infectious diseases. Stephan Pozdzioch presents regulations and legal texts : legal documents of the WHO, the World Health Organization and

Martina GLIBER de la Fondation Mérieux nous présente les expériences de l'enseignement à distance dans le réseau Euro-Mediterranean Public Health Information System (EMPHIS).

3PM TO 3.10PM OPENING SPEECH JACQUES DUBUCS, Chair of the Societal and Cultural Innovation Strategic Working Group at ESFRI, and Head of the Department of Social Sciences and Humanities, French

Intervenant : Robert Barouki, Inserm, directeur de l’UMR Toxicologie, pharmacologie et signalisation cellulaire Rappel du concept d’exposome et des différents moyens de l’explorer (différentes

Bernard Swynghedauw speaks in favour of a truly comprehensive ecology of health. He especially wants to better take into account the microbiota in the public health issues. He also raises the question

Randomised controlled trials, health agencies and consumer organisations: the case of Intrinsa and Flibanserin Randomized controlled trials (RCT) are now considered the ‘gold standard’ of clinical